Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aduro Biotech Inc.

www.adurobiotech.com

Latest From Aduro Biotech Inc.

ASCO Review: Progress Is Where You Find It

In another year roundly critiqued as being “quiet” on major clinical advances, the American Society of Clinical Oncology annual meeting allowed other areas to shine. 
ASCO Clinical Trials

ASCO Review: Progress Is Where You Find It

In another year roundly critiqued as being “quiet” on major clinical advances, the American Society of Clinical Oncology annual meeting allowed other areas to shine. 

ASCO Clinical Trials

Hitting Refresh: Aduro CEO On Company Cuts, Pipeline Programs And Alliances

Aduro Biotech announced a “strategic reset” in January 2019 that will see the Californian company center around two core pipeline programs, cut its headcount and focus on pharma partnerships. Stephen Isaacs, chair, president and CEO of the company, speaks to In Vivo about his vision for Aduro as the 2020s approach, and the challenges a smaller biotech faces when balancing multiple big pharma agreements.

C-Suite Speaks Growth

Finance Watch: Bitcoin For Biopharma? Agenus Gives BEST A Shot

Investors in a February Biotech Electronic Security Token (BEST) offering will be able to put their money behind a single Agenus asset – the PD-1 inhibitor AGEN2034. Also, financial and strategic updates from Gossamer, Aduro, Novo's REPAIR Impact Fund and more.

Financing Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
    • Vaccines
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Aduro BioTech
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Aduro Biotech Inc.
  • Senior Management
  • Stephen T Isaacs, Chmn., Pres. & CEO
    Jennifer Lew, CFO
    Andrea van Elsas, PhD, CSO
    Dimitry Nuyten, MD, PhD, CMO
  • Contact Info
  • Aduro Biotech Inc.
    Phone: (510) 848-4400
    740 Heinz Ave.
    Berkeley, CA 94710-2224
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register